Inhalation formulation technologies

Skyepharma has a range of proprietary inhalation formulation technologies to enhance performance or overcome challenges in the development of Dry Powder Inhaler (DPI) and Metered Dose Inhaler (MDI) products. These technologies can also be applied to nasal and nebuliser formulations.

Our technologies are available for licensing by our partners for incorporation into in-house developments. Alternatively we can apply these technologies on your behalf in our own GMP laboratories to solve complex formulation challenges in the development of a wide range of inhalation products.

Technology Application Benefit


Addition of magnesium stearate to DPI formulations

Improved dose uniformity and stability, especially with respect to moisture


Addition of sodium cromoglycate to MDI formulations

Improved stability especially with moisture sensitive compounds


Addition of magnesium stearate to MDI formulations

Improved physical stability, dose uniformity and extension of storage shelf-life


Addition of CO2 or N2O to MDI formulations

Finer MDI aerosols, enabling a significant increase in respirable dose


Production of sub-micron particles stabilised in HFA propellant for pMDI delivery

Targeted delivery of drug to the small airways (e.g. for systemic delivery) or enhanced efficacy

> Inhalation licensing opportunities
> Inhalation device technologies

> Download a leaflet [PDF 740 KB] 

Contact us to find out how we can help with your inhalation development.

Copyright 2014, Skyepharma. All Rights Reserved. Skyepharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 46-48 Grosvenor Gardens, London SW1W 0EB, United Kingdom

Contact addresses

Skyepharma PLC
46-48 Grosvenor Gardens

Tel: +44 207 881 0524

Fax: +44 207 881 1199

E-mail us

Skyepharma AG
Eptingerstrasse 61
4132 Muttenz

Tel: +41 61 467 5555

Fax: +41 61 467 5500

E-mail us

This website works best using cookies.